Nature Reviews Clinical Oncology

Vol. 22, Issue 8 Issue 8 2025
14
Articles

Articles in this Issue

Second-line tarlatamab improves OS in SCLC

David Killock Aug 01, 2025 pp. 544-544 10.1038/s41571-025-01047-5

The next generation of immunotherapies for lung cancers

Shen Zhao, Hongyun Zhao, Weiwei Yang et al. Aug 01, 2025 pp. 592-616 10.1038/s41571-025-01035-9

Adding durvalumab to perioperative FLOT improves gastric cancer outcomes

David Killock Aug 01, 2025 pp. 543-543 10.1038/s41571-025-01046-6

Promises and pitfalls of multi-cancer early detection using liquid biopsy tests

Jonathan C. M. Wan, Peter Sasieni, Nitzan Rosenfeld Aug 01, 2025 pp. 566-580 10.1038/s41571-025-01033-x

Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC

Diana Romero Aug 01, 2025 pp. 545-545 10.1038/s41571-025-01043-9

T-DXd effective as second-line therapy in G/GEJ cancers

Peter Sidaway Aug 01, 2025 pp. 544-544 10.1038/s41571-025-01044-8

A new first-line standard-of-care for BRAFV600E-mutated mCRC

Diana Romero Aug 01, 2025 pp. 543-543 10.1038/s41571-025-01042-w

Neoadjuvant nivolumab plus chemotherapy improves overall survival in resectable NSCLC

Peter Sidaway Aug 01, 2025 pp. 545-545 10.1038/s41571-025-01045-7

Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer

Li-Bo Tang, Ying-Long Peng, Ji Chen et al. Aug 01, 2025 pp. 546-565 10.1038/s41571-025-01029-7

Novel colorectal cancer screening methods — opportunities and challenges

Melina A. McCabe, Anthony J. Mauro, Robert E. Schoen Aug 01, 2025 pp. 581-591 10.1038/s41571-025-01037-7

Surrogate end points in oncology: aligning drug development incentives and patient needs

Matthew Vogel, Rona Yaeger, David J. Stewart et al. Aug 01, 2025 pp. 617-618 10.1038/s41571-025-01031-z

Reply to ‘Surrogate end points in oncology: aligning drug development incentives and patient needs’

Vinay Prasad Aug 01, 2025 pp. 619-620 10.1038/s41571-025-01032-y

Empowering oncologists: a practical approach to overcoming barriers to clinical trial enrolment

Changchuan Jiang, Ryan D. Nipp, Tian Zhang Aug 01, 2025 pp. 541-542 10.1038/s41571-025-01038-6

Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials

Ghulam Rehman Mohyuddin, Aaron M. Goodman Aug 01, 2025 pp. 539-540 10.1038/s41571-025-01034-w

All Issues

Issue 7 - Issue 7 11 Issue 6 - Issue 6 10 Issue 5 - Issue 5 10 Issue 4 - Issue 4 10 Issue 3 - Issue 3 10 Issue 2 - Issue 2 9 Issue 1 - Issue 1 12
Issue 9 - Issue 9 11 Issue 8 - Issue 8 14 Issue 7 - Issue 7 10 Issue 6 - Issue 6 9 Issue 5 - Issue 5 11 Issue 4 - Issue 4 10 Issue 3 - Issue 3 12 Issue 2 - Issue 2 8 Issue 12 - Issue 12 13 Issue 11 - Issue 11 9 Issue 10 - Issue 10 8 Issue 1 - Issue 1 12

Journal Info

Publisher Springer Science and Business Media LLC
ISSN 1759-4774
E-ISSN 1759-4782
Subject Medicine
Language English
View Full Journal Page